Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Large-scale Study Started on Antihypertensive Combination Therapy: Jikei Univ. Group
June 21, 2004
- 5 NCEs Including Octreotide to Be Included in NHI List
June 21, 2004
- Large-Scale Study on Mosapride in Functional Dyspepsia Starts
June 21, 2004
- Chuikyo Members Call For Revision of Drug Pricing Rules
June 21, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
June 21, 2004
- Korosho Holds Hearings on Progress of Action Plan
June 21, 2004
- MEDICAL DEVICE NEWS IN BRIEF
June 21, 2004
- White Paper on Manufacturing Urges International Competitiveness
June 21, 2004
- DIAGNOSTIC NEWS IN BRIEF
June 21, 2004
- REGULATORY NEWS IN BRIEF
June 21, 2004
- Iryo Proverbs Reveal Japanese Spirit (20)
June 21, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
June 21, 2004
- WORLD NEWS IN BRIEF
June 21, 2004
- 30% Copayment Rate Affecting Medical Visits: Korosho Survey
June 21, 2004
- NEW PRODUCTS
June 21, 2004
- Members of Patient Groups Show Strong Dissatisfaction with Physicians: OPIR Survey
June 21, 2004
- To Aggressively Increase Deals with Top 10 Makers: Mr Bessho of Suzuken
June 21, 2004
- PRESS SEMINAR
June 21, 2004
- Ethical Drug Market Grows 3.6% to \7.97 Trillion in FY2003: IMS Japan
June 21, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 21, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…